Trial Profile
Children Toxine Botulinum Detrusor Injection in Neurogenic Vesical Hyperactivity Syndrom: Non Inferiority Multicenter Controlled Therapeutic Study Between Two Reported Weight's Doses
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jul 2017
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Hyperactivity; Neurogenic bladder; Urinary incontinence
- Focus Therapeutic Use
- Acronyms TBIDE
- 27 Jul 2017 Status changed from recruiting to completed.
- 08 Jul 2016 New trial record